Quick comparison: what most people want to know
- Drug class — Semaglutide is a GLP-1 receptor agonist (approved brands Ozempic, Wegovy, Rybelsus). Retatrutide is an investigational triple agonist (GLP-1/GIP/glucagon) still in clinical trials.
- Weight-loss efficacy (trial context) — Semaglutide 2.4 mg shows around ~15% average weight loss at 68 weeks in obesity trials. Early phase 2 data for retatrutide reported up to ~24% average loss at 48 weeks at higher doses. These are not head‑to‑head studies.
- Approval in Australia — Semaglutide is TGA‑registered (different brands/indications). Retatrutide is not approved and generally only accessible via clinical trials.
- Safety — Both cause GLP‑1–class gastrointestinal effects. Retatrutide’s glucagon receptor activity may raise heart rate and has ongoing safety evaluation due to its investigational status.
- Who might suit what? — Today, most people who are eligible and seeking an evidence‑backed option consider semaglutide or tirzepatide. Retatrutide is a potential next wave option if and when approved.
Mechanisms: how retatrutide and semaglutide differ
The key distinction is the number of metabolic pathways targeted.
- Semaglutide (GLP‑1 RA) — Mimics GLP‑1 to slow gastric emptying, reduce appetite, and improve glycaemic control. Brands include Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral formulation).
- Retatrutide (triple agonist) — Investigational agent that activates GLP‑1, GIP, and glucagon receptors. The additional glucagon receptor activity may contribute to higher energy expenditure alongside appetite effects, which could explain strong early weight‑loss signals. Long‑term benefit‑risk remains under investigation.
Evidence snapshot: results to date
There are no head‑to‑head trials between retatrutide and semaglutide yet. Cross‑trial comparisons are only indicative and can be confounded by different designs and populations.
- Semaglutide (Wegovy 2.4 mg) — Obesity trials report about ~15% mean body‑weight reduction at 68 weeks, with improvements in waist circumference, blood pressure, and glycaemic markers.
- Retatrutide (phase 2) — Early data reported up to ~24% mean weight loss at 48 weeks at higher doses, with modelling suggesting additional loss beyond one year. Signals of improved glycaemic control were also observed. Confirmation in larger, longer phase 3 programs is required.
Bottom line: semaglutide has robust, long‑term real‑world use and regulatory approval. Retatrutide shows promising early efficacy but remains investigational.
Access in Australia
- Semaglutide — TGA‑registered. Access varies by indication and brand:
- Ozempic: type 2 diabetes treatment via prescription.
- Wegovy: chronic weight management via prescription (eligibility criteria apply).
- Rybelsus: oral semaglutide, prescription‑only.
- Retatrutide — Not TGA‑approved. Access is generally limited to clinical trials. See Is Retatrutide Legal in Australia? and Buy Retatrutide Australia for legal and safety considerations.
Dosing and administration
- Semaglutide for weight loss (Wegovy) — Once‑weekly injection with a stepwise titration over several months to reduce gastrointestinal side effects, typically targeting 2.4 mg weekly if tolerated. See Semaglutide Dosage Guide for an overview.
- Retatrutide — Once‑weekly subcutaneous dosing is being studied with gradual escalation to higher doses. Final dose ranges, devices and protocols will depend on regulatory outcomes and product labelling, if approved. See Retatrutide Dosage Guide for current trial‑based context.
Side effects and safety considerations
- Shared/class effects (GLP‑1) — Nausea, vomiting, diarrhoea/constipation, abdominal pain. Risks include gallbladder issues, rare pancreatitis, and potential hypoglycaemia when combined with certain diabetes medicines. GLP‑1 RAs carry a class warning about medullary thyroid carcinoma based on rodent data (discuss personal/family history of MTC/MEN2 with your doctor). See Semaglutide Side Effects.
- Retatrutide‑specific considerations — As a triple agonist, early studies note similar GI effects plus heart‑rate increases likely related to glucagon receptor activity. Full long‑term safety is still being established in phase 3 trials. See Retatrutide Side Effects.
People with pancreatitis history, significant gastrointestinal disease, severe renal/hepatic issues, or certain endocrine tumours require careful medical review before considering GLP‑1–based therapies.
Which option may suit different situations?
- Need an approved, widely used option now — Semaglutide is established, with clear eligibility pathways and monitoring plans for obesity and type 2 diabetes care.
- Watching next‑generation efficacy — Retatrutide’s early results are compelling, but until approval, it remains an investigational candidate.
- Diabetes, insulin resistance, or PCOS — GLP‑1 RAs like semaglutide have substantial data across glycaemic and weight‑related endpoints. See Semaglutide for Insulin Resistance and Semaglutide for PCOS.
- Exploring dual/triple agonists — Consider reading Retatrutide vs Tirzepatide and Semaglutide vs Tirzepatide Weight Loss to understand step‑up options and trade‑offs.
Frequently asked questions
Which is better for weight loss: retatrutide or semaglutide?
Early phase 2 data for retatrutide reported higher mean weight loss at 48 weeks than what semaglutide showed in separate trials, but there are no head‑to‑head studies. Semaglutide is proven and approved; retatrutide is promising but still in trials.
Is retatrutide available in Australia?
No routine access. Retatrutide is not TGA‑approved and is generally limited to clinical trials. See Is Retatrutide Legal in Australia?.
What are the main side differences?
Both can cause gastrointestinal effects typical of GLP‑1–based therapies. Retatrutide’s glucagon receptor activity may raise heart rate; its long‑term safety profile is still being evaluated.
How do costs compare?
Semaglutide costs depend on brand, dose, and availability. See Semaglutide Cost Australia. Retatrutide does not have standard pricing because it is not approved; see Retatrutide Cost Australia for context.
Does retatrutide help fatty liver?
Early signals suggest reductions in liver fat and improved metabolic markers in trials, but larger studies are needed. See Retatrutide for Fatty Liver.
What if I can’t tolerate semaglutide?
Alternatives include dose adjustments, supportive strategies, or considering other agents like tirzepatide. Discuss with a prescriber; see Mounjaro (Tirzepatide) Australia Guide.
Can I take retatrutide and semaglutide together?
This is not an approved strategy. Combination or sequencing should only be considered within clinical trials or specific medical guidance.
Where do I start?
Review the GLP‑1 Australia Guide and Weight Loss Injections Australia, then speak with a clinician about eligibility and risks.
Get help choosing between retatrutide and semaglutide
Have a clinician review your goals, medical history and eligibility. Submit the form below and we’ll connect you with information and next steps.
Final takeaway
Semaglutide is today’s approved, widely used GLP‑1 option with clear long‑term data and defined access pathways in Australia. Retatrutide is a promising triple agonist with strong early results, but it remains investigational until phase 3 data and regulatory reviews are complete.
If you are deciding now, base the choice on eligibility, safety, tolerability and availability of approved therapies. Keep an eye on retatrutide as the next wave potentially arrives.